Abstract
Angiotensin II (Ang II) type 1 (AT1) receptor is a member of the G protein-coupled receptor superfamily and contains 359 amino acids. AT1 receptor blockers (ARBs, e.g., eprosartan, losartan, candesartan, valsartan, telmisartan, olmesartan, irbesartan, and azilsartan) have been developed and are available for clinical use, and basic and clinical studies have shown that ARBs are useful for preventing the development of cardiovascular disease. While most ARBs have common molecular structures (biphenyl-tetrazol and imidazole groups), they also show slightly different structures. Some of the benefits conferred by ARBs may not be class-specific effects, and instead may be molecule-specific effects. Their common molecular structures are thought to be responsible for their class effects, whereas their slightly different structures may be important for promoting molecule-specific effects. This review focuses on current evidence regarding the class- and molecule-specific differential effects of ARBs from basic experiments to clinical settings.
Keywords: Angiotensin II type receptor blocker, cardiovascular disease, molecular structures, class-specific effects, molecule-specific effects.
Current Pharmaceutical Design
Title:Class- and Molecule-specific Differential Effects of Angiotensin II Type 1 Receptor Blockers
Volume: 19 Issue: 17
Author(s): Satoshi Imaizumi, Shin-ichiro Miura, Eiji Yahiro, Yoshinari Uehara, Issei Komuro and Keijiro Saku
Affiliation:
Keywords: Angiotensin II type receptor blocker, cardiovascular disease, molecular structures, class-specific effects, molecule-specific effects.
Abstract: Angiotensin II (Ang II) type 1 (AT1) receptor is a member of the G protein-coupled receptor superfamily and contains 359 amino acids. AT1 receptor blockers (ARBs, e.g., eprosartan, losartan, candesartan, valsartan, telmisartan, olmesartan, irbesartan, and azilsartan) have been developed and are available for clinical use, and basic and clinical studies have shown that ARBs are useful for preventing the development of cardiovascular disease. While most ARBs have common molecular structures (biphenyl-tetrazol and imidazole groups), they also show slightly different structures. Some of the benefits conferred by ARBs may not be class-specific effects, and instead may be molecule-specific effects. Their common molecular structures are thought to be responsible for their class effects, whereas their slightly different structures may be important for promoting molecule-specific effects. This review focuses on current evidence regarding the class- and molecule-specific differential effects of ARBs from basic experiments to clinical settings.
Export Options
About this article
Cite this article as:
Imaizumi Satoshi, Miura Shin-ichiro, Yahiro Eiji, Uehara Yoshinari, Komuro Issei and Saku Keijiro, Class- and Molecule-specific Differential Effects of Angiotensin II Type 1 Receptor Blockers, Current Pharmaceutical Design 2013; 19 (17) . https://dx.doi.org/10.2174/1381612811319170005
DOI https://dx.doi.org/10.2174/1381612811319170005 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Exploring the Cardio-metabolic Relevance of T-cadherin: A Pleiotropic Adiponectin Receptor
Endocrine, Metabolic & Immune Disorders - Drug Targets Pharmacological Modulations of the Renin-Angiotensin-Aldosterone System in Human Congestive Heart Failure: Effects on Peripheral Vascular Endothelial Function
Current Vascular Pharmacology Polycystic Ovarian Syndrome and Obstructive Sleep Apnea
Current Respiratory Medicine Reviews Calcific Aortic Valve Disease and Hypertension
Current Hypertension Reviews Caspases as Drug Targets in Ischemic Organ Injury
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Phenotyping of Chronic Obstructive Pulmonary Disease: Current Approaches and Future Directions
Current Respiratory Medicine Reviews Angiotensin (1-7) and other Angiotensin Peptides
Current Pharmaceutical Design Phytochemical Genistein in the Regulation of Vascular Function: New Insights
Current Medicinal Chemistry Estrogenic Compounds, Estrogen Receptors and Vascular Cell Signaling in the Aging Blood Vessels
Current Medicinal Chemistry Role of Oxidative Stress in the Development of Vascular Injury and its Therapeutic Intervention by Nifedipine
Current Medicinal Chemistry Does Handle Region Peptide Provide Benefits in Chronic Kidney Disease?
Current Hypertension Reviews Metabolic Syndrome, Mild Cognitive Impairment and Dementia
Current Alzheimer Research Glucocorticoids and Vascular Reactivity
Current Vascular Pharmacology cGMP-Dependent Protein Kinase in Regulation of the Pulmonary Circulation
Current Respiratory Medicine Reviews Latest Advances in Breast Sonography
Recent Patents on Medical Imaging 24-Hour Blood Pressure Control – A Predictor for Clinical Outcomes
Current Hypertension Reviews Platelet Activation in Atherogenesis Associated with Low-Grade Inflammation
Inflammation & Allergy - Drug Targets (Discontinued) Expression, Distribution and Regulation of Phosphodiesterase 5
Current Pharmaceutical Design Carvedilol: Just Another Beta-Blocker or a Powerful Cardioprotector?
Cardiovascular & Hematological Disorders-Drug Targets Examination of Hippocampal Differences Between Alzheimer Disease, Amnestic Mild Cognitive Impairment and Normal Aging: Diffusion Kurtosis
Current Alzheimer Research